Skip to content
Search

Latest Stories

Danish authority to pay £46 million over failed suit against Briton Sanjay Shah

Danish authority to pay £46 million over failed suit against Briton Sanjay Shah

LONDON’S high court has directed the Danish tax authority to pay a £46 million legal bill following its failed attempt to sue a British tycoon accused of a £1.5 billion fraud, the Times reported.

British businessman Sanjay Shah, 51, is a virtual prisoner in his Dubai mansion after the Danish authorities obtained a worldwide freezing order against more than £500m of his assets.


However, Shah insisted that he is the victim of politically motivated allegations by the Danish government that his London-based trading firm fraudulently claimed tax reductions through a scheme called “Cum-Ex”.

Shah’s company, Solo Capital Partners LLP, used an ambiguous tax loophole that allowed trading in shares with dividend payments, the newspaper said.

The trades exploited an interpretation of Danish tax laws that seemed to allow multiple investors to claim refunds on a dividend that was paid only once.

The Danish tax department claimed there is no evidence that real shares were used in the divided refunds claimed by Solo Capital and its clients.

Shah said the trades were legitimate.

In April, the Danish Customs and Tax Authority case against 100 defendants including Shah was dismissed by Justice Andrew Baker at the high court in London.

He revealed that the Danish authority was not entitled to enforce its own tax laws in an English court and ordered them to pay all defendants’ legal bills.

Baker said the case was “aggressively pursued, by a sovereign state with a willingness to expend effectively unlimited resources” and was “politically as well as financially motivated”.

The judge described the litigation as “the subject of ill-judged public statements by senior Danish politicians appearing to pre-judge the factual issues that would have fallen to be determined by the court”.

According to the Danish media, the tax authority has been ordered to pay by this week £46m of the £72m owed to lawyers, including more than £8m to Shah’s legal team.

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less